close

Вход

Забыли?

вход по аккаунту

?

128

код для вставкиСкачать
The Prostate Supplement 6: 1-2 (I996)
INTRODUCTION
Proceedings of the International Conference on
Androgenic Hormones, Prostate Cancer, and
Benign Prostatic Hyperplasia
In 1993 one of us (M.H.) attended a workshop on
“Intermittent Androgen Suppression In Prostate
Cancer” in Seattle, Washington. An aspect of this
meeting included discussing basic and clinical research highlighting the varied biological activity of
closely related androgenic compounds in males. Even
as a trained oncologist, the spectrum of action of
these compounds in health and disease was amazing.
As a result, it became obvious that a future conference focusing in a detailed manner on the role of
androgens in the physiologic regulation of the prostate and in the initiation, treatment, and progression
of prostate cancer is needed.
The complexity of the androgen effect is just unfolding as more research is being carried out as a
result of the surge in prostate research funding. For
example, we are just beginning to understand why
castration does not cure prostate cancer and how the
presence and absence of androgens may contribute to
progression and how to manipulate androgens as a
means of preventing prostate cancer. It is the improved understanding that will lead clinicians, often
frustrated by the unpredictable biology of this disease, to better prevention and therapeutic strategies.
The conference on ”Androgenic Hormones, Prostate Cancer and Benign Prostatic Hyperplasia,” sponsored by the Departments of Medicine and Urology at
Wayne State University, was therefore organized to
provide a forum for direct interaction, education, and
exchange of information between basic and clinical
scientists and to discuss the state of the art in
androgen research as it relates to prostate cancer and
benign prostatic hyperplasia. We believed that having basic and clinical scientists in one place would
encourage the definition of areas in which further
collaborative efforts are needed. Forty national and
international experts in the field were invited and
seven major areas provided focal discussion points:
androgen physiology and biology, normal and abnor-
0 1996 Wiley-Liss, Inc.
mal regulation of androgen action, benign prostatic
hyperplasia theories of pathogenesis, 5a-reductase
inhibitors and their role in prostate cancer prevention, androgenic and molecular biology of prostate
cancer, prostate growth regulation, and mechanisms
of progression to androgen independence. A specific
effort was made to bring together researchers from
disciplines that characteristically would not regularly
interact with each other, but who now share common
ground in the study of androgen pathophysiology
of the prostate. Cancer biologists, endocrinologists,
medical oncologists, urologists, biochemists, and molecular biologists all made valuable contributions.
Many participants were exposed to new viewpoints
from these diverse research orientations. Through
this proceedings we attempt to provide the reader
with a flavor of areas discussed during this meeting.
In the current economic climate, a conference of
this nature can only be possible through a partnership between interested parties. In addition to a grant
from the National Cancer Institute, this conference
was supported by very generous contributions from
several pharmaceuticals companies. These contributions made the conference and this proceedings possible and provided a wonderful example of a healthy
partnership aiming at promoting education and science. We would like to also acknowledge the invaluable contributions of Ms. Judy Vargo, without whom
this conference would not have been possible.
ACKNOWLEDGMENT
This work was supported by National Cancer Institute grant lR13CA65936-01and grants from the following pharmaceuticals companies: TAP, Zeneca,
Pharmacia, Berlax-Canada, Inc., Glaxo, Inc., Merck
& Co., Inc., Merck Frost Canada 1nc.-Medical Research, Schering OncologyBiotech, Bristol-Myers
Squibb, Eli Lilly & Co.
2
Hussain and Montie
Maha Hussain, MD
James Montie, M D
Department of Medicine,
Division of Hematology/Oncologyand
Department of Urology
Wayne State University,
Detroit, Michigan
Dr. Montie is Currently at University of Michigan,
Section of Urology, Ann Arbor, MI
Документ
Категория
Без категории
Просмотров
4
Размер файла
112 Кб
Теги
128
1/--страниц
Пожаловаться на содержимое документа